GLP1R and diabetes mellitus: Since the reduction of glucose concentrations with the classic treatments in diabetes has not given the expected results in terms of cardiovascular protection, the therapeutic strategy with the new antidiabetic drugs such GLP-1 RAs should now focus on the modification of vascular risk factors [3].